Phase 1/2 Nivolumab + Plinabulin in NSCLC
The Phase 1/2 trial of Plinabulin with Nivolumab in patients with non-small lung cancer will evaluate the combination.
Animal studies provide indications of an immune MOA, which primarily acts through activation and proliferation of tumor antigen-specific CD4 T-cells, a white blood cell active in immune responses.
28 days per cycle; Plinabulin (IV): Day 1, 8, 15;Nivolumab (IV): Day 1, 15
Patients with 2nd/3rd line NSCLC
S. Yeh et al., A Phase 1 Trial Combining Plinabulin and Nivolumab for Metastatic Squamous NSCLC.,International Association for the Study of Lung Cancer, Abstract 602 /, P2.01-087, 2015.
Results of this trial were published as follows:
Nivolumab in Combination with Plinabulin in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
Nivolumab and Plinabulin in Treating Patients with Stage IIIB-IV, Recurrent, or Metastatic Non-Small Cell Lung Cancer